Compare AbCellera Biologics Inc (ABCL) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs SAP SE — how do they compare? AbCellera Biologics Inc trades at $9.68 (market cap $2.99B), while SAP SE trades at $203.65 (market cap $240.81B). The key difference: SAP SE is far larger — about 80.5× AbCellera Biologics Inc's market cap, and SAP SE pays a 1.4% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SAP | |
|---|---|---|
Market Cap | $2.99B | $240.81B |
Sector | Health | Technology |
52-Week High | $9.76 | $280.46 |
52-Week Low | $2.78 | $146.38 |
Enterprise Value | $2.58B | $239.52B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
SAP trades at $208.55, up 1.16% today, near its consensus price target of $209.67. The stock shows a bullish technical trend with strong moving averages, though oscillators indicate overbought conditions. Recent Q2 2026 earnings missed EPS estimates but revenue grew, driven by cloud demand. The company maintains robust profitability with a net income margin of 20.41% and solid cash flow from operations of $9.16B in 2025.
Outlook is mixed: AI and cloud growth offer upside, but profit guidance cuts and execution risks pose challenges. Analysts are generally bullish (53.49% buy ratings), yet investors should weigh high valuation multiples against competitive pressures in enterprise software. Near-term resistance lies at $211.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
